CellCentric also announced a number of changes to its board of directors: Barrie Ward has been appointed nonexecutive chairman, and Sue Foden becomes a nonexecutive director. As chief executive officer of KuDos Pharmaceuticals, Dr. Ward led the company from its inception through to its acquisition by AstraZeneca in December 2005. He also serves as chairman of Avant Immunotherapeutics and Onyvax. Dr. Foden is a trustee of the Institute of Cancer Research and chairs its intellectual property subcommittee. She was previously at Celltech, the Cancer Research Campaign (now Cancer Research UK) and Merlin BioSciences.
Richard Chin has been appointed to the position of president and CEO of OXiGENE (Waltham, MA, USA), replacing Frederick Driscoll. Dr. Chin, a current member of OXiGENE's board of directors, was most recently senior vice president and head of global development for Elan Corp., with worldwide responsibility for clinical development, regulatory, biostatistics, quality assurance/compliance, chemistry manufacturing and control, safety and medical affairs.
This is a preview of subscription content, access via your institution
